Mitigates Hyperglycemia-induced Upregulated Wnt/β-catenin Expression and Kidney Injury in Diabetic Rats

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2018 Mar 28

PMID 29581743

Citations 12

Authors

Baochao Chang

Weidong Chen

Yan Zhang

Ping Yang

Lei Liu

Affiliations

Soon will be listed here.

Abstract

Aberrant activation of the Wnt/β-catenin pathway contributes to the development of diabetic nephropathy (DN); however, treatment with (TW) may be beneficial for patients with DN. The aim of the present study was to evaluate the effect of TW on Wnt/β-catenin expression in the kidneys of diabetic rats. Male Sprague-Dawley rats were randomly injected with vehicle (control) or streptozotocin to induce diabetes. Diabetic rats were then randomly treated with vehicle (sodium carboxymethyl cellulose; SCC), TW combined with SCC (8 or 16 mg/kg) or irbesartan (50 mg/kg) daily for 8 weeks. Metabolic parameter levels and renal pathological changes were examined. mRNA and protein expression of Wnt-1, glycogen synthase kinase (GSK)-3β, β-catenin, nuclear factor (NF)-κB and transforming growth factor (TGF)-β1 in the kidneys of rats from all groups were measured. Compared with the DM group, metabolic parameters and morphological parameters, apart from blood glucose levels, were significantly improved in TW-treated rats (all P<0.01). Furthermore, levels of Wnt-1, β-catenin, NF-κB-p65 and TGF-β1 mRNA and protein were significantly reduced in the kidneys of TW-treated rats compared with DM rats, whereas levels of GSK-3β mRNA and protein did not differ significantly between any of the groups; however, the expression of P-GSK-3β protein was significantly decreased in the kidneys of TW-treated rats compared with the DM group. The protective effects of TW tended to be dose-dependent and were an improvement compared with irbesartan treatment in diabetic rats. Therefore, the results of the present study indicated that treatment with TW mitigated hyperglycemia-induced upregulated Wnt-1 and β-catenin expression in kidney tissues and ameliorated diabetes-induced kidney injury in rats.

Citing Articles

Non-dialyzable uremic toxins and renal tubular cell damage in CKD patients: a systems biology approach.

Asadi R, Shadpour P, Nakhaei A Eur J Med Res. 2024; 29(1):412.

PMID: 39123228 PMC: 11311939. DOI: 10.1186/s40001-024-01951-z.

The effects of Hook F on renal outcomes in type 2 diabetic kidney disease patients with severe proteinuria: a single-center cohort study.

Cheng Y, Liu Y, Lin L, Li D, Peng L, Zheng K Ren Fail. 2024; 46(1):2295425.

PMID: 38178377 PMC: 10773657. DOI: 10.1080/0886022X.2023.2295425.

Efficacy and safety of Tripterygium wilfordii multiglucoside for idiopathic membranous nephropathy: a systematic review with bayesian meta-analysis.

Wang H, Liu H, Xue X, Wang Q, Yuan J Front Pharmacol. 2023; 14:1183499.

PMID: 37608889 PMC: 10442163. DOI: 10.3389/fphar.2023.1183499.

Inhibition of RIP1-RIP3-mediated necroptosis attenuates renal fibrosis via Wnt3α/β-catenin/GSK-3β signaling in unilateral ureteral obstruction.

Piao S, Ding J, Lin X, Nan Q, Xuan M, Jiang Y PLoS One. 2022; 17(10):e0274116.

PMID: 36223414 PMC: 9555645. DOI: 10.1371/journal.pone.0274116.

Shenkang injection improves chronic kidney disease by inhibiting multiple renin-angiotensin system genes by blocking the Wnt/β-catenin signalling pathway.

Wang Y, Liu H, Ren L, Suo P, Zou L, Zhang Y Front Pharmacol. 2022; 13:964370.

PMID: 36059935 PMC: 9432462. DOI: 10.3389/fphar.2022.964370.

References

Hao L, Pan M, Zheng Y, Wang R . Effect of and polyglycosidium on podocytes in rats with diabetic nephropathy. Exp Ther Med. 2014; 7(6):1465-1470. PMC: 4043575. DOI: 10.3892/etm.2014.1670. View

Zhu B, Wang Y, Jardine M, Jun M, Lv J, Cass A . Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62(3):515-30. DOI: 10.1053/j.ajkd.2013.02.374. View

He Y, Shi S, Zhang R, Shen W, Tu J, Ding Z . In vitro immunosuppressive and cytotoxic activities of Tripterygium wilfordii extract. Drug Chem Toxicol. 2014; 38(2):145-51. DOI: 10.3109/01480545.2014.919583. View

Li Z, Xu J, Xu P, Liu S, Yang Z . Wnt/β-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes. Cell Prolif. 2013; 46(1):76-85. PMC: 6496492. DOI: 10.1111/cpr.12010. View

Liu S, Li X, Li H, Liang Q, Chen J, Chen J . Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study. BMC Nephrol. 2015; 16:200. PMC: 4669631. DOI: 10.1186/s12882-015-0199-x. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K . Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia. 2003; 46(6):843-51. DOI: 10.1007/s00125-003-1099-3. View

Ma R, Zhao N, Zhang W . [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients]. Zhonghua Nei Ke Za Zhi. 2013; 52(6):469-73. View

Ma Z, Zhang X, Li L, Yang W, Wang S, Guo X . Tripterygium Glycosides Tablet Ameliorates Renal Tubulointerstitial Fibrosis via the Toll-Like Receptor 4/Nuclear Factor Kappa B Signaling Pathway in High-Fat Diet Fed and Streptozotocin-Induced Diabetic Rats. J Diabetes Res. 2015; 2015:390428. PMC: 4549548. DOI: 10.1155/2015/390428. View

10.

Ma R, Liu L, Liu X, Wang Y, Jiang W, Xu L . Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy. Exp Ther Med. 2013; 6(3):649-656. PMC: 3786875. DOI: 10.3892/etm.2013.1226. View

11.

Zain M, Awan F . Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy. Pak J Pharm Sci. 2014; 27(5):1379-91. View

12.

He W, Kang Y, Dai C, Liu Y . Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2010; 22(1):90-103. PMC: 3014038. DOI: 10.1681/ASN.2009121236. View

13.

He W, Dai C, Li Y, Zeng G, Monga S, Liu Y . Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009; 20(4):765-76. PMC: 2663839. DOI: 10.1681/ASN.2008060566. View

14.

Ren F, Tang L, Cai Y, Yuan X, Huang W, Luo L . Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy. Ren Fail. 2015; 37(4):548-61. DOI: 10.3109/0886022X.2015.1012995. View

15.

Dai C, Stolz D, Kiss L, Monga S, Holzman L, Liu Y . Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol. 2009; 20(9):1997-2008. PMC: 2736766. DOI: 10.1681/ASN.2009010019. View

16.

Gao Q, Shen W, Qin W, Zheng C, Zhang M, Zeng C . Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant. 2010; 25(11):3539-47. DOI: 10.1093/ndt/gfq245. View

17.

Wu Y, Ren K, Liang C, Yuan L, Qi X, Dong J . Renoprotective effect of total glucosides of paeony (TGP) and its mechanism in experimental diabetes. J Pharmacol Sci. 2009; 109(1):78-87. DOI: 10.1254/jphs.08112fp. View

18.

Doi T, Mima A, Matsubara T, Tominaga T, Arai H, Abe H . The current clinical problems for early phase of diabetic nephropathy and approach for pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract. 2008; 82 Suppl 1:S21-4. DOI: 10.1016/j.diabres.2008.09.013. View

19.

Ho C, Lee P, Hsu Y, Wang F, Huang Y, Lin C . Sustained Wnt/β-catenin signaling rescues high glucose induction of transforming growth factor-β1-mediated renal fibrosis. Am J Med Sci. 2012; 344(5):374-82. DOI: 10.1097/MAJ.0b013e31824369c5. View

20.

Zhang W, Zhao L, Su S, Xu X, Wu Y . Total glucosides of paeony attenuate renal tubulointerstitial injury in STZ-induced diabetic rats: role of Toll-like receptor 2. J Pharmacol Sci. 2014; 125(1):59-67. DOI: 10.1254/jphs.13173fp. View